Posts by: Stacy Grieve, PhD

News

Results from a Phase 3 clinical trial show that adding Adcetris (brentuximab vedotin) to a chemotherapy regimen reduces the risk of disease progression, death, or use of additional anticancer therapies for ... Read more

October 25, 2017

Pre-treatment with CD37 Antibody Enhances Amount of Betalutin to NHL Tumors, Study Finds

News

Preliminary trial results show that pre-treatment with the antibody lilotomab may increase the amount of Nordic Nanovector‘s investigational therapy Betalutin that reaches tumor lesions in patients with non-Hodgkin’s lymphoma (NHL). Representatives from ... Read more

October 10, 2017

Gazyva Reduces Risk of Disease Progression in Follicular Lymphoma Patients, Clinical Trial Finds

News

Interim analysis of the GALLIUM (NCT01332968) clinical trial shows that treatment with Gazyva plus chemotherapy improves progression-free survival in patients with advanced, CD20-positive, untreated follicular lymphoma. The GALLIUM trial set ... Read more

May 16, 2017

Injected Rituxan Is as Effective and Safe as IV Form as Lymphoma Treatment, Study Concludes

News

Injections of Rituxan (rituximab) for non-Hodgkin lymphoma are as effective as intravenous administrations, take five minutes instead of an hour and a half, and require far less medical-staff monitoring time, according to ... Read more

May 3, 2017May 3, 2017

EMA Grants Orphan Drug Designation for PQR309 Therapeutic In Diffuse Large B-Cell Lymphoma

News

The European Medicines Agency (EMA) has granted Swiss pharmaceutical firm PIQUR Therapeutics orphan drug designation for PQR309 to treat patients with diffuse large B-cell lymphoma (DLBCL). Claudia Pluess, the company’s senior ... Read more